Chugai Pharmaceutical Co., Ltd. announced that it has filed a patent infringement lawsuit at the
Tokyo District Court as follows.
Date of Complaint: December 5, 2018
Reasons for the Action: Chugai alleges that the anti-C5 antibody ALXN1210 (ravulizumab) product, an investigational drug developed by Alexion Pharma Godo Kaisha (Japan Regional Headquarters), infringes some of its Japan patents (Patent No. 4954326 and No. 6417431) relating to its proprietary antibody engineering technology. Thus, Chugai filed a patent infringement lawsuit against Alexion requesting a judgment that the ALXN1210 product infringes Chugai’s Japan patent and injunctive relief precluding manufacturing and selling of the ALXN1210 product in Japan.
Defendant Name: Alexion Pharma Godo Kaisha
Address: 18-14 Ebisu 1-Chome, Shibuya-ku, Tokyo, JAPAN
Prospects No changes are expected to be made to Chugai’s financial prospects at this point.